Related Experiment Video
Updated: Apr 5, 2026
04:13
Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
Published on: September 27, 2024
955
Bridging waitlist delays with interim buprenorphine treatment: initial feasibility
Stacey C Sigmon1, Andrew C Meyer2, Bryce Hruska2
1Department of Psychiatry, University of Vermont, Burlington, VT, United States; Department of Psychology, University of Vermont, Burlington, VT, United States.
Addictive Behaviors
|August 11, 2015
Summary
Technology-assisted interim buprenorphine treatment shows promise for opioid-dependent adults on waitlists. This approach reduced illicit opioid use and craving, demonstrating high adherence and feasibility.
Area of Science:
- Addiction Medicine
- Digital Health
- Pharmacotherapy
Background:
- Opioid dependence treatment often involves lengthy waitlists, increasing patient risk.
- Interim dosing offers a harm reduction strategy during treatment delays.
- Novel technologies can potentially support remote medication management.
Purpose of the Study:
- To assess the feasibility of technology-assisted interim buprenorphine treatment.
- To evaluate the initial efficacy of this novel approach for waitlisted patients.
- To examine patient adherence and acceptability of the intervention.
Main Methods:
- Pilot study involving 10 opioid-dependent adults on a waitlist.
- Buprenorphine induction followed by 12 weeks of observed dosing and take-home medication via a secure device.
- Daily monitoring through an Interactive Voice Response (IVR) platform and random checks.
Main Results:
- High rates of illicit opioid abstinence (90% at weeks 2 & 4, 60% at week 12).
- Significant reductions in past-month illicit opioid use, withdrawal symptoms, and craving.
- Excellent adherence to buprenorphine (99%), IVR calls (97%), and random checks (82%).
Conclusions:
- Technology-assisted interim buprenorphine treatment is a feasible and promising approach.
- This method can mitigate risks associated with treatment waitlists.
- Further large-scale randomized trials are warranted to confirm efficacy.
Related Concept Videos
01:26Oral Drug Delivery Systems: Continuous-Release Systems
222
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
222
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
358
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
358
01:28Pulmonary Tuberculosis V
883
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
883
01:23Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
96
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s...
96
01:28IV Infusion to Oral Dosing: Conversion Methods
143
The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...
143
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
1.5K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.5K